SamaCare
SamaCare is prior authorization software for specialty drugs billed under the medical benefit, used by retina, oncology, neurology and rheumatology practices and infusion centers to create, submit, track and follow up on authorizations, one at a time or in bulk. SamaCare Plus, launched in November 2025 with select practices and rolling out more widely in 2026, adds an AI layer drawn from nearly 2 million past authorizations: it selects the payer's form, prepares clinical documentation, flags known denial triggers before submission, submits and checks status, and surfaces recommendations at key decision points, with checkpoints so nothing goes to a payer without practice approval. Alerts and AI to human escalation catch delays, and practice level benchmarks compare approval rates and timelines by payer, therapy and pathway.
The platform is free to practices, funded by drug manufacturer services and market insights; connected EHRs can add their own charge, such as ModMed's $20 per provider a month. Integration guides cover ModMed and NextGen Enterprise with two way document transfer, OncoEMR over FHIR and Nextech. CVP Physicians, an eye care network of 84 locations and 145 prescribers, cut time to resolution 59% and denials 19% in its first year on the platform, and SamaCare cites 84% faster resolution and 42% fewer denials across customers. Eye Care Partners, One Oncology and Vivo Infusion, a Plus design partner, are among named users, in a network SamaCare puts at more than 40,000 providers. The San Francisco company, led by chief executive Syam Palakurthy, raised a $17 million Series B and was a 2026 Prix Galien USA finalist.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
SamaCare Plus is the AI module: patterns from nearly 2 million medical benefit authorizations drive form selection, documentation assembly, flags for known denial triggers and recommendations at decision points, and the product can carry a case from preparation through submission and status checks once staff approve.
The base platform, a shared queue for creating, submitting and tracking authorizations with alerts and benchmarks, works without the model and is what most practices use for free. Plus's automated case preparation would not exist without the learned layer, while the platform around it has value of its own.
Practice approval is required before anything is submitted, including cases assembled in bulk, and Plus shows staff its recommendations and reasoning at critical decision points. Intelligent alerts flag delays and hand cases from AI to staff when issues arise. That sets a firm approval boundary.
What is not described is the trigger for the handoff, such as an incomplete chart, a payer request for more information or an uncertain form choice, and how the queue treats a case whose supporting evidence is missing, which is the part of the structure a practice would want spelled out.
Plus is built on patterns from nearly 2 million medical benefit prior authorizations and a 40,000 provider network, and it was designed with specialty practices and infusion centers, Vivo Infusion among them. Those patterns drive form selection, payer requirements, documentation assembly and the recommendations staff see at decision points, and the same data feeds benchmarks by payer, therapy and pathway. That explains what informs the system.
No production model is named, the line between learned recommendations and fixed payer rules at each step is not drawn, and how a model update is evaluated and introduced to practices is not described.
Authorization records move from the practice's EHR to SamaCare and on to payers, and the privacy policy allows third party infrastructure and information services. No subprocessor list, hosting provider or model provider is named, so whether patient records reach an outside model service when Plus prepares a case, and on what retention and training terms, is unknown.
McKesson, Cencora and the American Rheumatology Network are business partners rather than named processors of the data, and the life sciences customers buying insights receive deidentified data under terms that are not public.
CVP Physicians, an eye care network of 84 locations and 145 prescribers, centralized its authorizations on SamaCare and reports a 59% drop in time to resolution and a 19% drop in denials in its first year, without control sites or a case count. Across customers SamaCare cites 84% faster resolution, 42% fewer denials and 70% faster time to care, with no method. Those results belong to the platform rather than Plus. Vivo Infusion's senior director of patient services says Plus speeds determinations by cutting manual review, without figures, and no measured result for AI prepared cases exists yet.
Authorizations carry diagnoses, medications and supporting clinical records, and the privacy terms describe how provider and patient information is collected, transmitted to payers and deidentified under the HIPAA Privacy Rule, with limits on reidentification. Deidentified authorization activity also funds the free platform through market insights sold to life sciences companies.
How long forms and attachments prepared by Plus are kept, whether identifiable records train the models, and how an incorrectly prepared packet is investigated as a model failure are not stated, so the commitments stay general.
The privacy policy covers the service as well as the website, naming diagnoses, medications and supporting clinical data among what the service handles, and states that protected health information is governed by a separate business associate agreement with each provider. It also describes deidentification under the HIPAA Privacy Rule and limits on reidentification.
The agreement itself is not public, so its subcontractor terms, and whether different terms apply to Plus, the EHR interfaces or practices whose free access is funded by data insights, cannot be read before signing.
A completed SOC 2 audit and HIPAA compliance work covering the company's data and systems are named in its data use FAQ. The report type, auditor, audit period and covered systems are not given, and whether Plus, launched in late 2025, falls within scope is not stated. No trust center or retrievable report exists, and the providers page makes no security claim at all, linking only to the privacy policy and terms. Each connected EHR's own security assurance covers that EHR rather than SamaCare's service, so the SOC 2 statement is the only outside check named for how authorization data is protected.
Authorization is for specialty drugs a practice has already chosen to prescribe: the software selects forms, assembles clinical evidence, flags known denial triggers in payer rules and submits after staff approval, and the insurer makes the coverage decision. Nothing in the product selects a therapy or directs care. SamaCare makes no device claim, and its scope as administrative software for the medical benefit authorization process matches that position. The data insights sold to life sciences companies are a commercial product separate from the practice workflow and make no clinical claim either.
Recommendations draw on authorizations seen across a network of more than 40,000 providers and on payer rules, and benchmarks break down approval rates and timelines by payer, therapy and submission pathway. Those describe the data behind the guidance. No results compare how often Plus prepares a case correctly, or how its guidance performs, across specialties, payers, drugs or patient groups, and no review process for changes to the model is described. For a tool that learns from past payer behavior, whether it carries those patterns forward unevenly is the question left open.
Every packet can be reviewed before it reaches a payer, built in checkpoints mean nothing is submitted without practice approval, and support gives practices named contact channels, with internal tools for investigating authorization error notices. Those let a practice catch and correct a bad packet. No compensation, indemnity or remediation commitment applies when an AI prepared case is incomplete and the drug is delayed or denied, and the payer, not SamaCare, makes the coverage decision. Getting approvals the first time is presented as an aim rather than a promise, and the terms guarantee no authorization result, so the checkpoint is the protection.
Integration guides cover four record systems: ModMed and NextGen Enterprise with two way patient document transfer, OncoEMR through a FHIR connection that pulls demographics, coverage and documents into SamaCare on demand, and a Nextech interface. The guides are specific about record locations, user roles, activation and what is written back, and SamaCare takes part in industry standards work on payer and interoperability requirements.
CVP Physicians and Eye Care Partners show the platform running at scale, but no named practice is tied to a specific two way interface in production. McKesson, Cencora and the American Rheumatology Network are partners on the commercial side.
SamaCare runs as a hosted application controlled from the United States, and its terms state that customer data is stored in a database the company manages there. Integration setup works through practice credentials and EHR access, with no customer managed or dedicated deployment offered.
The storage commitment names the country but not the region, and processing and backup paths for attachments and model inputs, tenant isolation and any support access from abroad are not described, so residency is committed while isolation is left open.
Practices pay nothing for the base platform, which drug manufacturer services and market insights for life sciences companies fund, so the free price rests on the data a practice's authorizations generate. Connected EHRs can charge their own fees: ModMed lists $20 per provider a month for its interface, and the OncoEMR connection carries no fee but needs an agreement.
Plus is available to select practices with no separate price or eligibility terms shown, and a practice starts by requesting access or a demo. Amounts paid by life sciences customers are not disclosed.
Specialty practices and ambulatory infusion centers are the buyers, in retina and ophthalmology, oncology, neurology and rheumatology, for drugs given in an office or infusion setting under the medical benefit, with buy and bill retina benchmarks and a dedicated neurology launch. CVP Physicians shows use at a large eye care network, and Plus was designed with practices including Vivo Infusion.
Named logos include One Oncology, Arthritis Health Associates, Eye Care Partners and Infusion for Health, with testimonials from Central Florida Retina and Intracare Health Services. Platform results are deepest in eye care, while Plus has no results by specialty yet.
Alternatives to SamaCare
Other products that do the same kind of work as SamaCare, and what each one does.
Forus, formerly Tandem (renamed in May 2026 with no change in ownership), is a medication access platform that automates the path from prescription to therapy at the point of prescribing.
Develop Health automates medication access for prescribers, pharmacies, payers and life sciences teams.
Latent Health sells pharmacy intelligence software that helps health systems get patients onto specialty, infusion and retail medications faster.
Mandolin automates the administrative work required to start and sustain specialty drug treatment. Its agents read referrals and clinical records, investigate insurance benefits, estimate patient costs, assemble prior authorization submissions and follow claims through payer portals and calls.
Ember AI is an AI revenue integrity platform for specialty physician practices, surgery centers and health systems, sold on preventing denials upstream and recovering them downstream.
AI orchestration platform for provider side revenue cycle, founded 2022, positioned as an overlay on the systems of record rather than a replacement.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Free base platform for practices
$0 baseline
|
Practices pay nothing for the base platform, which drug manufacturer services and data insights for life sciences companies fund. SamaCare Plus is available to select practices with no separate price shown. | Practice data is handled under a separate business associate agreement with each provider. The agreement text and its subcontractor terms are not public. | SamaCare provides virtual implementation training. ModMed charges $20 per provider per month for its interface, and the OncoEMR connection has no fee but requires an agreement. | Vendor Published |
The free offer covers the prior authorization platform. Connected EHRs can charge for their interfaces, and Plus eligibility and pricing are set with SamaCare.